Discoverpoint-of-care toolslike our insurance coverage checker for CGMs and medications and dosing info for T2D

MCT2D Resource: Dosing Information for SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Type 2 Diabetes

Key dosing information for SGLT2-I and GLP1-RAs including dose escalation, pen and needle RX considerations, proven benefits for ASCVD, CKD, HFrEF, HFpEF, and DKD.

Providers, have you used this tool? Give us your feedback to help improve it for others

Tags:

For ProvidersNon-videoPDFCreated-By-MCT2DPoint-of-care

Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit www.valuepartnerships.com. Although Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes work in partnership, the opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

PATIENT STORIES POINT-OF-CARE-TOOLS SUBMIT A CASE SUMMARY SUBMIT FEEDBACK

MCT2D Resource: Dosing Information for SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Type 2 Diabetes

Subscribe to the MCT2D Newsletter